Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

Abstract:
-VisEn's Expanding Probe Portfolio Broadens Molecular Imaging Applications in Key Areas of Disease Research and Drug Development-

VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

WOBURN, MA | Posted on June 8th, 2007

VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the market launch of its MMPSense(TM) molecular imaging probe for real time imaging of matrix metalloproteinase (MMP) related activities in vivo. The launch further expands the company's proprietary molecular imaging probe and system product platforms to now even more broadly enable real-time imaging of molecular and biologic activity in vivo, including ranges of protease activities, angiogenesis, bone generation, vascular permeability, and inflammatory responses. By imaging and quantifying disease-related biological activities and therapeutic interventions in vivo, VisEn technology platforms enable expanded areas of research, increasingly efficient drug development, and advanced personalized clinical medicine into the future.

The VisEn MMPSense(TM) probe, developed from the Company's proprietary fluorescence imaging probe platforms, is an activatible in vivo fluorescence probe capable of imaging MMP activity in tumors and other sites of inflammation in vivo. In its non-active state, the probe is not fluorescent, but it emits strong fluorescence in response to MMP activity in vivo. According to the National Cancer Institute, MMPs are a group of enzymes that can break down proteins, such as collagen, that are normally found in the spaces between cells in tissues (i.e., extracellular matrix proteins). It is known that MMP activity is involved in many disease-related phenomena, including cancer propagation, invasion and metastasis, inflammation, host response, and in areas of cardiovascular disease. On May 2 of this year, VisEn Medical and its exclusive distribution partner in Asia, Olympus Corporation, announced the launch of MMPSense as well as VisEn's nanoparticle- based AngioSpark and AminoSpark molecular imaging probes, in Japan and other key Asian markets.

"Today's MMPSense product launch marks a significant advance in our drive to provide a complete package of translational molecular imaging solutions for measuring and quantifying disease progression and drug effect in vivo," said Kirtland G. Poss, President and CEO of VisEn Medical. "Our partners in drug development and clinical research worldwide can now access these important new tools that will help the whole field better understand, define and treat molecular targets and disease processes in an unprecedented fashion."

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Probe Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers in vivo. VisEn probes are designed to be compatible with a range of fluorescence imaging systems, including planar fluorescence imaging systems, intravital microscopes, and VisEn's FMT tomographic imaging system.

Additional product information can be obtained by calling Customer Support at VisEn Medical: 781-932-6875, ext. 315; or via email at: ; or at http://www.visenmedical.com/ .

####

About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing the industry's highest performing fluorescence molecular imaging technology platforms, from research through medicine. The Company also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. VisEn recently announced a multi-year joint research and development program with Merck & Co to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group.

For more information, please click here

Contacts:
Customer Support
VisEn Medical
781-932-6875, ext. 315

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

Teijin Aramidís carbon nanotube fibers awarded with Paul Schlack prize: New generation super fibers bring wave of innovations to fiber market September 25th, 2014

Nanotubes help healing hearts keep the beat: Rice University, Texas Childrenís Hospital patch for defects enhances electrical connections between cells September 23rd, 2014

Immune system is key ally in cyberwar against cancer: Rice University study yields new two-step strategy for weakening cancer September 23rd, 2014

Announcements

UT Arlington researchers develop transparent nanoscintillators for radiation detection for medical safety and homeland security September 29th, 2014

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Nanoparticles Used to Improve Quality of Bone Cement September 29th, 2014

'Pixel' engineered electronics have growth potential: Rice, Oak Ridge, Vanderbilt, Penn scientists lead creation of atom-scale semiconducting composites September 29th, 2014

Tools

Iranian Scientists Determine Grain Size, Minimize Time of Nanocomposite Synthesis September 29th, 2014

Oxford Instruments launches 3rd annual Indian nanotechnology seminars in Kolkata and Delhi - sharing expertise with Nanotechnology researchers in India September 25th, 2014

Contributing to the spirit of the IYCR 2014 September 24th, 2014

New NIH/DOE Grant for Life Science Studies at NSLS-II: Funding will support operation of three powerful experimental stations designed to reveal detailed structures of proteins, viruses, and more September 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE